2022年7月26日 · Antigen-combining sites of the camelid heavy-chain antibody variable domain (VHH) are constructed by three complementarity-determining regions (CDR1, CDR2 and CDR3). We prepared cDNA using mRNA extracted from peripheral lymphocytes of alpacas that had been non-immunized or immunized with human serum …

The single-domain antibody (VHH) is a promising building block for a number of antibody-based applications. Ribosome display can successfully be used in the production of VHH. However, the construction of the expression cassette, confirmation of …

2018年10月1日 · To demonstrate that the GPI anchor is adaptable to other neutralizing antibodies, we designed and produced an mRNA encoding for a single-domain camelid antibody (VHH), capable of neutralizing...

2024年11月22日 · We report an LNP named LNP67 that delivers mRNA to murine HSCs in vivo, primary human HSCs ex vivo and CD34+ cells in rhesus monkeys (Macaca mulatta) in vivo at doses of 0.25 and 0.4 mg kg−1.

2022年2月23日 · To quantify functional delivery, we used mRNA encoding glycosylphosphatidylinositol (GPI) membrane–anchored VHH as a reporter gene, as it has been shown to achieve durable surface expression (>28 days) that can be detected by immunofluorescence staining with anti-VHH antibodies .

2020年1月30日 · Taking advantages of small sizes and unique structures of the single-domain antibodies, here, we presented a novel approach to rapidly deliver the nanobody/variable domain of heavy chain of heavy-chain antibody (V H H) into living cells via introducing its coding mRNA, which was generated by in vitro transcription.

scfv和vhh都是基因工程化细胞药物非常好的选择，无论是car-t还是car-nk等细胞治疗，其中最核心的与靶细胞结合的car都是由scfv或者vhh构成。而且，vhh由于分子量小、易于人源化、理化性质稳定，越来越多的细胞治疗使用vhh。 三、结论与展望

2018年9月9日 · Single-domain antibody (e.g., Nanobody, VHH antibody) is a promising scaffold for therapeutic and diagnostic reagents. To expand the range of target molecules, in vitro selection using cell-free display technologies such as cDNA display is useful and powerful because of their huge libraries and robust stability.

2024年1月19日 · Van Hoecke等人编码了一种工程化的双特异性VHH构建体(RiboBiFE)，该构建体此前已被证明通过将甲型流感病毒基质蛋白2胞外域(M2e)特异性VHH与选择性结合小鼠Fc受体IV(Fcƴ;图1C)。与在支气管灌洗液中检测到48小时的mRNA编码的核糖相比，气管内(IT)注射重组bis特异性蛋白在 ...

2023年3月27日 · 2021年12月Moderna在nature medicine杂志公开了mRNA-1944（编码CHKV-24抗体的mRNA）临床一期的数据，证明了RNA-encoded antibodies的安全性。 NCT03829384临床试验共入组了38个健康人，单剂量分别是0.1mg/kg，0.3mg/kg，0.6mg/kg，或者单周给药2次，各0.3mg/ml（图15）。